

## ACO Name and Location

Chrysalis Medical Services, LLC  
Previous Names: N/A  
4888 Loop Central Drive  
Suite 300  
Houston, TX 77081

## ACO Primary Contact

<i>Primary Contact Name</i>	Adrienne Opalka
<i>Primary Contact Phone Number</i>	914-281-0827
<i>Primary Contact Email Address</i>	Adrienne.Opalka@wellcare.com

## Organizational Information

### ACO participants:

<b>ACO Participants</b>	<b>ACO Participant in Joint Venture (Enter Y or N)</b>
David Gabros	N
Shore Atlantic Geriatrics, LLC	N
Island Medical Professional Association	N
Suketu Nanavati Md Pa	N
Medcom Health Services, PA	N
Frank P. Matteace, MD PA	N
Howard J Sperling MD PC	N
Reliance Medical Group, LLC	N
Arnold S Bacarro Md Pa	N
Richard G. Olarsch, DO PC	N
Southern Ocean Primary Care Associates, LLC	N
Burton Waisbren	N

**ACO governing body:**

Member			Member's Voting Power – Expressed as a percentage or number	Membership Type	ACO Participant Legal Business Name/DBA, if Applicable
Last Name	First Name	Title/Position			
Bassett	Shawn	Voting Member	23%	Other	N/A
Miller	Walter	MD, Voting Member	15%	ACO participant representative	Southern Ocean Primary Care Associates
Regis	Jon	MD, Voting Member	15%	ACO participant representative	Reliance Medical Group LLC
Waisbren	Burton	MD, Voting Member	15%	ACO participant representative	Burton Waisbren
Nanavati	Suketu	MD, Voting Member	15%	ACO participant representative	Suketu Nanavati Md Pa
Baccaro	Arnold	MD, Voting Member	15%	ACO participant representative	Arnold S Bacarro Md Pa
Papaccio	Vince	Voting Member	2%	Medicare Beneficiary Representative	N/A

**Key ACO clinical and administrative leadership:**

Adrienne Opalka	ACO Executive
Walter Miller	Medical Director
Michael Yount	Compliance Officer
Walter Miller, MD	Quality Assurance/Improvement Officer
Shawn Bassett	ACO Executive Director

**Associated committees and committee leadership:**

Committee Name	Committee Leader Name and Position
<i>Management Committee</i>	Walter Miller, MD, Chair

**Types of ACO participants, or combinations of participants, that formed the ACO:**

- ACO professionals in a group practice arrangement
- Networks of individual practices of ACO professionals

**Shared Savings and Losses**

**Amount of Shared Savings/Losses**

- First Agreement Period
  - Performance Year 2017, \$0
  - Performance Year 2016, \$0
  - Performance Year 2015, \$0

**Shared Savings Distribution**

- First Agreement Period
  - Performance Year 2017
    - Proportion invested in infrastructure: N/A
    - Proportion invested in redesigned care processes/resources: N/A
    - Proportion of distribution to ACO participants: N/A
  - Performance Year 2016
    - Proportion invested in infrastructure: N/A
    - Proportion invested in redesigned care processes/resources: N/A
    - Proportion of distribution to ACO participants: N/A
  - Performance Year 2015
    - Proportion invested in infrastructure: N/A
    - Proportion invested in redesigned care processes/resources: N/A
    - Proportion of distribution to ACO participants: N/A

**Quality Performance Results**

2017 Quality Performance Results:

ACO#	Measure Name	Rate	ACO Mean
------	--------------	------	----------

ACO-1	CAHPS: Getting Timely Care, Appointments, and Information	76.77	80.60
ACO-2	CAHPS: How Well Your Providers Communicate	92.37	93.13
ACO-3	CAHPS: Patients' Rating of Provider	91.58	92.31
ACO-4	CAHPS: Access to Specialists	83.63	83.32
ACO-5	CAHPS: Health Promotion and Education	62.72	62.30
ACO-6	CAHPS: Shared Decision Making	74.95	75.85
ACO-7	CAHPS: Health Status/Functional Status	71.79	73.05
ACO-34	CAHPS: Stewardship of Patient Resources	28.45	25.68
ACO-8	Risk Standardized, All Condition Readmission	15.57	15.01
ACO-35	Skilled Nursing Facility 30-day All-Cause Readmission measure (SNFRM)	18.81	18.46
ACO-36	All-Cause Unplanned Admissions for Patients with Diabetes	70.57	53.95
ACO-37	All-Cause Unplanned Admissions for Patients with Heart Failure	88.47	79.16
ACO-38	All-Cause Unplanned Admissions for Patients with Multiple Chronic Conditions	68.43	61.74
ACO-43	Ambulatory Sensitive Condition Acute Composite (AHRQ* Prevention Quality Indicator (PQI #91))	2.26	1.93
ACO-11	Use of Certified EHR Technology	100.00	98.48
ACO-12	Medication Reconciliation	89.69	75.32
ACO-13	Falls: Screening for Future Fall Risk	57.22	74.38
ACO-44	Imaging Studies for Low Back Pain	81.82	67.32
ACO-14	Preventive Care and Screening: Influenza Immunization	72.34	72.52
ACO-15	Pneumonia Vaccination Status for Older Adults	64.51	72.92
ACO-16	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	77.44	70.69
ACO-17	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	91.13	90.48
ACO-18	Preventive Care and Screening: Screening for Clinical Depression and Follow-up Plan	53.46	61.98

ACO-19	Colorectal Cancer Screening	43.22	64.58
ACO-20	Breast Cancer Screening	46.38	70.05
ACO-42	Statin Therapy for the Prevention and Treatment of Cardiovascular Disease	77.58	79.89
ACO-27	Diabetes Mellitus: Hemoglobin A1c Poor Control	29.04	16.74
ACO-41	Diabetes: Eye Exam	28.86	50.37
ACO-28	Hypertension (HTN): Controlling High Blood Pressure	73.66	71.47
ACO-30	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	66.08	86.86

Please note, the ACO-40 Depression Remission at 12 months quality measure is not included in public reporting due to low samples.

- For 2017 Quality Performance Results please visit: <https://data.cms.gov/Special-Programs-Initiatives-Medicare-Shared-Savin/2017-Shared-Savings-Program-SSP-Accountable-Care-O/gk7c-vejx/data>
- For 2016 Quality Performance Results please visit: <https://data.cms.gov/Special-Programs-Initiatives-Medicare-Shared-Savin/2016-Shared-Savings-Program-SSP-Accountable-Care-O/3jk5-q6dr/data>
- For 2015 Quality Performance Results please visit: <https://data.cms.gov/Special-Programs-Initiatives-Medicare-Shared-Savin/Medicare-Shared-Savings-Program-Accountable-Care-O/x8va-z7cu/data>

Note: In the Quality Performance Results file(s) above, search for “Chrysalis Medical Services, LLC” or “Chrysalis - An Accountable Care Organization” to view the quality performance results. This ACO can also be found by using the ACO ID A47655 in the public use files on data.cms.gov.

## Payment Rule Waivers

No, our ACO does not use the SNF 3-Day Rule Waiver.

## *Arrangements Disclosed*

### **REQUIRED PUBLIC DISCLOSURE FOR USE OF AN ARRANGEMENT ENTERED INTO UNDER THE ACO PARTICIPATION WAIVER**

*Chrysalis Medical Services, LLC (the “ACO”) participates in the Medicare Shared Savings Program (“MSSP”) under a contract with the Centers for Medicare & Medicaid Services (“CMS”). The Secretary of the Department of Health and Human Services (“HHS”) by and through CMS and the Office of Inspector General, HHS has provided certain waivers of federal fraud and abuse laws deemed necessary by CMS to carry out the MSSP pursuant to a Final Waivers in Connection with the Shared Savings Program dated October 29, 2015, as may be amended, including the ACO Participation Waiver (“Participation Waiver”). On December 26, 2017, the Governing Body of ACO after previous discussions authorized, via unanimous written consent, an arrangement with Laboratory Corporation of America Holdings (“LabCorp”) under which LabCorp will collaborate with ACO to provide ACO with laboratory data and test result values for ACO’s assigned beneficiaries, and jointly develop an outreach program to ACO’s providers/suppliers to provide educational services and information concerning. In addition to educational services, ACO will provide ACO providers/suppliers with, among other things, their applicable test result values and an analysis of such laboratory data so they can improve their patients’ care. Finally, LabCorp will provide a grant of funds to allow ACO to defray a portion of the costs to further develop and implement the program, including investment or modification of ACO’s administrative and clinical systems, and otherwise assisting the ACO’s efforts with respect to the MSSP. Consistent with the requirements of the Participation Waiver, after discussing the proposed arrangement with LabCorp, the Board of Directors made a bona fide determination that an arrangement with LabCorp as described below is reasonably related to the purpose of the MSSP and authorized such arrangement. The collaboration is related to the purposes of the MSSP as it augments ACO’s ability to:*

- Promote evidence-based medicine and patient engagement;*
- Meet the requirements for reporting quality and cost measures coordinating care;*
- Establish clinical and administrative systems;*
- Meet the clinical integration requirements of the MSSP;*
- Evaluate the health needs of ACO’s aligned population;*
- Communicate clinical knowledge and evidence based medicine to Medicare beneficiaries;*
- and*
- Develop standards for beneficiary access and communication, including beneficiary access to medical records.*

*Accordingly, ACO entered into this arrangement having determined that it meets all conditions to enable ACO to avail itself of the Participation Waiver.*